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Abstract
Substantial evidence shows that the hypophyseal–pituitary–adrenal (HPA) axis and
corticosteroids are involved in the process of addiction to a variety of agents, and the adrenal
cortex has a key role. In general, plasma concentrations of cortisol (or corticosterone in rats or
mice) increase on drug withdrawal in a manner that suggests correlation with the
behavioural and symptomatic sequelae both in man and in experimental animals.
Corticosteroid levels fall back to normal values in resumption of drug intake. The possible
interactions between brain corticotrophin releasing hormone (CRH) and proopiomelano-
cortin (POMC) products and the systemic HPA, and additionally with the local CRH–POMC
system in the adrenal gland itself, are complex. Nevertheless, the evidence increasingly
suggests that all may be interlinked and that CRH in the brain and brain POMC products
interact with the blood-borne HPA directly or indirectly. Corticosteroids themselves are
known to affect mood profoundly and may themselves be addictive. Additionally, there is a
heightened susceptibility for addicted subjects to relapse in conditions that are associated
with change in HPA activity, such as in stress, or at different times of the day. Recent studies
give compelling evidence that a significant part of the array of addictive symptoms is directly
attributable to the secretory activity of the adrenal cortex and the actions of corticosteroids.
Additionally, sex differences in addiction may also be attributable to adrenocortical function:
in humans, males may be protected through higher secretion of DHEA (and DHEAS), and in
rats, females may be more susceptible because of higher corticosterone secretion.
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Introduction
The purpose of this review is to demonstrate the critical
role of the adrenal cortex in addiction and additionally to
propose that sex differences in adrenocortical function
may contribute to sex differences in addiction. Where it
is clear, the sex of experimental animals or of human
subjects in the cited studies is stated, although in most
cases sex differences were not emphasized.
There is a long history of associating addiction with
the adrenal. Indeed, it was well before the adrenocortical
hormones were even characterized that morphine toxicity
was linked to the adrenal gland. Thus, Lewis (1) and
Mackay & Mackay (2) showed that adrenalectomy
increased morphine sensitivity in female rats, and chronic
treatment with morphine in males or methadone in
either sex produces adrenocortical hypertrophy (3, 4).
Consequently, there has been interest in the actions of the
hormones of the adrenal as possible agents in addiction
from the time of their discovery. Treatment with cortisone
(the therapeutic corticosteroid of choice at the time) was
soon applied in the management of meperidine and
morphine withdrawal symptoms in men (5), apparently
with beneficial effects, while Lovell associated alcoholism
and drug addiction with hypoadrenocorticism (6).
More systematic study then discounted corticoster-
oids along with other novel ‘cures’ for withdrawal
symptoms, and Fraser & Isbell (7) were the first to suggest
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that in fact withdrawal symptoms (from morphine) in
men were associated with eosinopaenia, a measure used
at that time to reflect high levels of circulating cortico-
steroids (8). Eosinophil counts swiftly normalized when
morphine was restored. These authors also found that
treatment with either cortisone or ACTH shortened the
period for development of withdrawal symptoms
in men, and therefore, they themselves could be con-
sidered a cause (7, 9, 10, 11). Indeed, chronic treatment
with corticosteroid can itself lead to later withdrawal
symptoms (12).
So there are fundamental questions on the role of
corticosteroids in addiction. Is the lower adrenocortical
activity in sustained morphine administration, and its
elevation when administration ceases, a cause or an effect
of addictive responses? Could the drive to addictive drugs
actually represent a drive to lower cortisol, with its
sequelae? Or is the heightened secretion of corticosteroids
in drug withdrawal simply a response to stress? We here
argue that the adrenal cortex has a critical role in the
acquisition of addiction and also in protection against it.
The hypophyseal–pituitary–adrenal axis in
the brain and addiction
In relation to addiction, far more attention has been paid
to hypophyseal–pituitary–adrenal (HPA) components in
the brain than to the systemic (i.e. blood-borne) HPA axis.
All the components are present in the brain, and, in
relation to the hypothesis that the adrenal itself is crucial
to addiction, it is important to unravel the relationship
between brain and systemic HPA function. This section
examines the evidence for brain HPA function in
addiction and shows that it is not autonomous, and its
function is closely regulated by and linked to the
systemic HPA.
Corticotrophin releasing hormone
Corticotrophin releasing hormone (CRH) is produced in
various parts of the brain (13). First, CRH exerts its
systemic effects following its release at the median
eminence by neuronal tracts that originate in the
paraventricular nucleus (PVN) of the hypothalamus.
CRH is transported to the corticotrophs of the anterior
pituitary via the hypophyseal portal system and then
stimulates the secretion of ACTH. ACTH is in turn carried
in the general circulation and stimulates the secretion of
corticosteroids in the adrenal cortex.
In addition, however, CRH, its receptors CRHR1 and
CRHR2, and also CRH binding protein (CRH-BP), which
modulates CRH actions, are found in other brain
locations, where CRH presumably acts primarily as a neuro-
transmitter. These sites include the cerebrocortex,
limbic system, hippocampus, amygdala, locus coeruleus,
olfactory bulb and cerebellum (14, 15, 16, 17, 18, 19, 20).
While the involvement of such extra hypophyseal CRH
with addiction may be independent of the HPA (18, 20),
there are certainly pathways through which it con-
tributes to the multifactorial regulation of hypothalamic
CRH (Fig. 1).
In the brain, CRH binds to both receptor types, CRHR1
and CRHR2. In addition to CRH itself, both these
receptors bind ligands of the urotensin family. The two
receptors mediate different responses; CRHR1 agonists
produce stress-related responses on which CRHR2 may
have less effect, while more potently depressing food
intake (21, 22, 23, 24).
There is certainly substantial evidence for the role
of CRH in addiction (18, 25), and particularly in
reinstatement, but the data are not always consistent.
For example, cocaine stimulates the HPA axis through a
hypothalamic/CRH-mediated mechanism in male rats
(26, 27), and although this is not invariably closely linked
to corticosterone (28), both Crh mRNA transcription
and circulating corticosterone are further increased on
cocaine withdrawal (29). In contrast, shock-induced
reinstatement of heroin or alcohol seeking clearly depends
on CRH, but not on corticosterone, according to some
authors (30, 31, 32). Nevertheless, adrenal function is
required during cocaine self-administration for sub-
sequent CRH-dependent shock-induced reinstatement
to occur (33). The modulator of CRH actions, CRH-BP,
is now emerging as an additional factor, although not
so widely studied in the addiction field (34, 35). Although
both corticosterone and ACTH secretion are increased by
acute alcohol exposure, they are inhibited in chronic
exposure (36, 37). Neither CRH nor cortisol is implicated
in cocaine reinstatement in squirrel monkeys (38).
With specific regard to morphine and the opioids,
it is clear that reduced circulating corticosteroid con-
centrations may be a consequence of opioid inhibition of
CRH secretion, acting through m- and k-type opioid recep-
tors in the male rat hypothalamus (39, 40, 41). In humans,
opioids directly inhibit CRH secretion and the HPA axis,
resulting in decreased circulating cortisol. In male rats,
the effect is biphasic, with early enhancement of CRH
(and the HPA) followed by inhibition after a few days of
treatment (41, 42); such responses are affected by stress
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review G P Vinson and C H Brennan Addiction and the adrenal
cortex
2–14 2 :R2
http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0028
 2013 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
in male rats (43). Indeed, the evidence suggests that
opioidergic mechanisms may at least partially underlie
both the behavioural effects of CRH in male rats (44) and
also the increase in CRH secretion under conditions of
stress. This may not be true in other situations such as the
increased HPA activity in adrenalectomized animals (45).
This double effect in rats may be because opioids have
differential effects on different cell types: they certainly
inhibit CRH secretion that is promoted by neurotransmit-
ters (46). The possibly critical involvement of opioids in
alcohol addiction in humans (47) has also been shown to
be exerted via other than HPA pathways (48).
There are clear differences between the actions of
different addictive drugs on Crh mRNA transcription in
the hypothalamus, and although alcohol acts directly on
the PVN, other drugs, including cocaine, nicotine and
cannabinoids, activate Crh transcription in other brain
sites (49). Adrenocortical activity may still be critical, for
example in reinstatement of cocaine addiction in male rats
(33). Timing of exposure is also significant; early exposure
can affect subsequent responses (50), and in male rats,
adolescent exposure to alcohol vapour blunts subsequent
adult Crh transcription response to acute alcohol (51).
The development of specific CRHR1 antagonists has
provided more information. CRHR1 blockade inhibits
further alcohol drinking in male rats habituated to a
high intake (52), and, in conjunction with additional
studies using Crh1 knockout animals, it has been shown
that CRHR1 signalling pathways are essential for sensi-
tization to alcohol addiction in male mice (53); a common
expression of neuroadaptations induced by repeated
exposure to addictive drugs is a persistent sensitized
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Figure 1
The expanded HPA axis. From (20, 49, 80, 82, 192, 193) and see text.
BNST, bed nucleus of stria terminalis; PFC, pre-frontal cortex; PVN,
paraventricular nucleus; VTA, ventral tegumental area (associated with
reward responses); CRH, corticotrophin releasing hormone; POMC,
proopiomelanocortin; C, stimulatory; K, inhibitory. Solid arrows show
proven regulation, and dotted arrows show postulated actions. Secreted
CRH is indicated in blue lettering, and sites of CRH and POMC signalling are
indicated in red and green respectively: here, arrows indicate regulatory
pathways that are unquestionably multifactorial but may include actions of
CRH and POMC peptides. The inhibitory effect of neural POMC peptides on
PVN CRH is particularly interesting, and, by comparison with other systems,
might suggest a negative feedback mechanism; however, there is little
evidence for reciprocal feedback of CRH on POMC in the brain. Instead,
regulation of neural POMC is multifactorial (e.g. (65, 67), and this is
primarily linked to its role in energy balance and nutrition, see text. There
is, however, much evidence to show the feedback of glucocorticoids on
CRH expression in several brain regions. Mostly, this is negative, except in
the amygdala, a key region in addiction (19), where it is positive.
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behavioural response to their stimulant properties. These
authors also show that acquisition and sensitization are
differentially regulated. Acquisition involves the HPA axis
and is inhibited by the glucocorticoid blocker mifepris-
tone as well as by CRHR1 blockade, whereas sensitization
is unaffected by mifepristone. Pastor et al. (53) propose
that this suggests a non-hypothalamic CRHR1-linked
pathway in sensitization. Different effects were seen in
methamphetamine (MA) responses, in which behavioural
sensitization measured as increased drug-induced loco-
motor activity was unaffected in Crh1 knockouts or by
the antagonist CP 154 526 in DBA/2J mice, whereas
deletion of Crh2 attenuated MA-induced behavioural
sensitization. Here, an action of endogenous urocortins
was suggested, focused in the basolateral and central
nuclei of the amygdala (54).
Proopiomelanocortin
Proopiomelanocortin (POMC) provides, in ACTH and
a-melanocyte stimulating hormone (a-MSH), the other
components of the HPA axis, and in this context, its
primary site of expression and processing is the anterior
pituitary and (in rodents) the pars intermedia. POMC is
also expressed in brain sites, primarily in projections from
the arcuate nucleus of the hypothalamus and from the
nucleus tractus solitarius of the brainstem (55, 56, 57). Its
primary role in the brain is the generation of a-MSH,
which participates in the regulation of food intake and in
the production of b-endorphin, pain control. a-MSH acts
through two of the melanocortin receptor (MCR) series,
MC3R and MC4R, and the latter may also regulate aspects
of pain recognition (25, 58).
POMC expression and processing suggests that
although ACTH and other POMC products such as
b-endorphin can be found in non-hypothalamic regions
of the brain or cerebrospinal fluid (59, 60), some may be
transported to the brain from the blood (60, 61). From
early development, the major adrenocortical-related
POMC product in the brain is a-MSH (62), presumably
associated with the distribution of the prohormone
convertases PC1 and PC2 (63, 64). By far, the major
focus of attention in this regard is the role of a-MSH with
leptin, ghrelin and agouti protein in the regulation of food
intake and energy balance (56, 62, 65, 66, 67, 68).
In addition to its role in energy balance, a-MSH
also plays a part in the physiology of addiction, and
MC4R, like CRH receptors, respond to morphine (69, 70,
71), and the behavioural effects of morphine or cocaine
are modulated by selective MC4R inhibition (72, 73).
Additionally, acute alcohol treatment reduced a-MSH
expression in hypothalamic and other brain locations in
rats, but chronic treatment enhanced it (74).
Of course, POMC processing in relation to addiction
cannot be considered purely in terms of its HPA-linked
functions. The production of b-endorphin leads inevitably
to direct effects on addiction pathways. Its main action
is mediated by m-receptors as are the opiates morphine,
heroin and methadone, and in humans, the endogenous
opiates are similarly inhibitory on HPA function, although
both stimulatory and inhibitory in rats (49, 75).
What has not been clear hitherto is whether the term
‘HPA axis’ can in reality be extended to these components
in the brain. In other words, it has been unclear whether,
for example, non-hypothalamic CRH provokes synthesis,
processing or release of POMC in the brain, but the
different locations of the expression of these components
may suggest it does not (Fig. 1). Similarly, there has really
been no evidence that brain CRH or POMC products have
any interaction with the adrenal cortex and the secretion
of glucocorticoids, other than via the hypothalamus. On
the contrary, it has sometimes been assumed that they do
not (e.g. (53)). However, neural glucocorticoid receptor
(GR) disruption, including in the PVN, ameliorates the
effects of anxiety and also results in heightened HPA
activity in male mice (76), consistent with the loss of
glucocorticoid inhibition of CRH (20, 77). In contrast,
forebrain-specific GR knockout, which does not involve
the PVN, increased anxiety behaviour but has the same
effect of diminishing glucocorticoid inhibition of CRH in
male mice (77). It is clear from this study that the HPA is
regulated partly by forebrain GR-mediated inhibition.
Accordingly, what needs to be unravelled is the signi-
ficance of the local brain CRH/POMC components in
distinction to that of the systemic HPA, and how
independent these systems really are in addiction.
Interaction between brain CRH and a-MSH
Although the main recognized function of a-MSH in the
brain, regulation of food intake and nutrition seems not to
be closely related to that of CRH, in fact there is ample
evidence of crosstalk between them. Certainly, like the
systemic HPA, POMC-processing neurones are activated
by stress and play a role in the consequent behavioural
response in male rats (78, 79). Furthermore, neuronal
POMC-derived peptides regulate hypothalamic CRH and
thus ACTH secretion in male and female mice (80).
Additionally, a-MSH stimulates Crh transcription in the
PVN of male rats (81, 82), although, like g-MSH, it also
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inhibits interleukin-1b-induced HPA activity, apparently
through central MCRs (83). That the circuit connecting
brain and systemic HPA is complete is suggested by the
finding that glucocorticoids enhance MC4R signalling in a
hypothalamic neuronal cell line (84). We can therefore
predict the existence of an extended HPA axis in which the
same components, CRH, POMC products and corticoster-
oids as in the classical system, also interact in the brain
(Fig. 1) with specific effects on mood and behaviour. The
two systems, brain and somatic, interact to the extent that
whatever physiological stimuli activate the systemic
system, broadly ‘stress’ and the clock, must also have
consequences on mood and behaviour.
Steroids in the brain
The spectrum of structures and functions of neurosteroids
is so wide as to form a branch of endocrinology (or at
least paracrinology) in its own right. Many are locally
synthesized, although usually requiring substrates from
non-neural sources. Oestrogens are prominent among
these and are produced by aromatase activity in the
hippocampus, acting, it is thought, on locally produced
C19 steroid substrates (85). They have roles in neural
plasticity (86) and neuroprotection (85, 87, 88) and
regulate the function of other neurally active agents,
including neuroprogesterone, which is also synthesized
locally (89). There are sex-related differences in the neural
responses to oestrogen (90, 91, 92). Oestrogen action in
the brain is mediated through classical oestrogen receptors
a and b and also through membrane metabotropic
glutamate receptors (93, 94). Neuroactive steroids that
primarily act through N-methyl-D-aspartate or gamma-
aminobutyric acid (GABA) receptors include the adrenal
androgen DHEA, which as DHEAS conjugate is the most
abundant steroid in human plasma (95, 96, 97, 98). DHEA
is not secreted by the rat adrenal cortex: its presence
and activity in the brain reflect its local synthesis (99).
DHEA and pregnenolone, both D5,3b-hydrosteroids,
are also opioid sigma receptor agonists, whereas pro-
gesterone, which has the D4,3-one configuration, is an
antagonist (100). Through their sigma-1 agonist actions,
pretreatment with DHEA or pregnenolone potentiates
cocaine-induced conditioned place preference (CPP)
behaviour in mice (100) but attenuates cocaine-seeking
behaviour (101). In patients, DHEA and DHEAS are
associated with beneficial actions in cocaine withdrawal
(102, 103), and the use of DHEA administration to
assist opioid withdrawal has been studied, with variable
outcomes (104, 105).
Other known neurosteroids include 3a-hydroxy-
5a-pregnan-20-one (tertrahydroprogesterone, allopregna-
nolone, THP) and 3a,21-dihydroxy-5a-pregnan-20-one
(tetrahydrodeoxycorticosterone, THDOC), and they are
formed in the brain from progesterone and deoxy-
corticosterone (106, 107). They have anxiolytic, anti-
convulsant and sedative activities and are known to be
elevated in both plasma and brain in response to ethanol
in rats (106, 108). In addition, the HPA axis is under tonic
GABA inhibition at the hypothalamic level (75). Impor-
tantly, production in the brain of both THP and THDOC
depends on precursor steroids of adrenal origin (106).
The corticosteroids themselves have neurological
effects, and brain concentrations of corticosterone cer-
tainly have relevance to addictive behaviour in male
rats (109), and see below. However, the relevance of local
brain synthesis of corticosteroids is unclear. Certainly, all
the required enzymes of the corticosteroid biosynthetic
pathway from cholesterol are present, notably in the
hippocampus, together with the StAR protein (110, 111,
112), but their level of production is likely to be low in
comparison with concentrations crossing the blood–brain
barrier, and they are not thought to be produced in the
brain to any great extent (113, 114). Remarkably then, of
the known neurosteroids, the corticosteroids may fall into
a group of their own being predominantly dependent on
an extraneural source: the adrenal cortex.
The role of the adrenal cortex
Corticosteroids and mood
Clearly, the role of corticosteroids in addiction cannot be
understood without reference to the nature of the
psychological and behavioural aspects of the actions of
corticosteroids themselves. Almost as the corticosteroids
were first characterized, their paradoxical capacity to
generate both euphoria and depression in humans has
been well known, although poorly understood (115, 116).
Changes in mood are a feature of chronic corticosteroid
therapy, with mild euphoria in the short term and
increases in severity of symptoms associated with
depression, or even psychosis in the long-term, and
these occur most frequently in women (116, 117, 118,
119, 120), although with large variations in incidence in
different studies. Moreover, both cortisol levels and the
response to ACTH are higher in depression or depressive
episodes (121), and animal experiments show that both of
these may be linked to high CRH secretion (29). It has
been suggested that corticosteroids may have a role in
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dopamine-related psychiatric disorders (122), and it has
also been speculated that some behavioural features in
animals and humans may result from structural or other
changes in the brain that corticosteroids may invoke, or
at least facilitate (114, 123, 124). Reduction of circulating
corticosteroid levels, in combination with other indices,
can also be used as a marker for response to anxiolytic
therapy (125, 126). It has been postulated that depression
in fact reflects GR desensitization, giving rise to impaired
glucocorticoid feedback at the hypothalamus, hence
increased HPA activity. In this model, one action of
antidepressants is thus to resensitize GR transcriptional
activity (125), independent of their action on monoamine
reuptake, but perhaps involving regulation of steroid
elimination from the cell through the multi-drug resist-
ance P-glycoprotein membrane transporter system (127,
128). Together, these studies suggest that corticosteroid-
evoked mood changes could be related to behavioural
responses to addiction.
Corticosteroids and addiction
Although the earlier association between the adrenal
cortex and addiction is derived largely from circumstantial
evidence, there are now data showing a direct causal link.
From their experiences with patients receiving chronic
steroid treatment, some authors have been willing to label
the corticosteroids as drugs of addiction themselves (129,
130, 131, 132, 133, 134), although much of the earlier
evidence is based on individual case reports. These
findings tend to suggest a close link between corticoster-
oids and addiction, a concept amply borne out by more
recent studies. Alcohol administration induces ACTH
secretion and thus adrenocortical stimulation in male
rats (106). In habituated men smoking high- but not low-
nicotine cigarettes, increased plasma ACTH and cortisol
occurs within minutes of smoking (135). Further evidence
for the crucial actions of elevated cortisol is given by its
association with impaired learning and memory in
abstinent cocaine-dependent men and women (136),
although higher basal cortisol levels are associated with
improved memory performance in healthy controls. These
effects on memory apparently reflect the inverted
U-shaped cortisol response curve; at low levels, increased
cortisol is beneficial to hippocampal cognitive responses,
but at higher levels, it is not (137). The degree of stress-
induced cortisolaemia and mood negativity is correlated
with increased positivity after amphetamine in men and
women (138).
Furthermore, much experimental evidence supports
the general concept (see Table 1). Male rats too self-
administer corticosterone in a manner that suggests
some degree of dependence (139, 140). Thus, de Jong
et al. (141) found that cocaine-induced locomotor
sensitization in adrenalectomized male mice was
restored by replacement of both adrenaline and corti-
costerone, and cocaine- or alcohol-induced behaviours
in female mice are inhibited in the presence of a GR
inhibitor (142). Additionally, if corticosteroid synthesis
is blocked, cocaine self-administration also relapses
according to some authors (143). Others find the reverse
that corticosterone facilitates relapse, although dexa-
methasone did not, suggesting mineralocorticoid
receptor (NR3C2, MR) involvement (144). Such effects,
like those of antipsychotic drugs, may be mediated
through the mesolimbic dopaminergic system (145,
146). It is striking that dopamine-dependent responses
to morphine require glucocorticoid receptors (147).
In experimental animals, the definitive evidence for
the pivotal role of the corticosteroids in addiction stems
from recent studies in the effects of GR over- and under-
expression. Brain-specific GR depletion in mice decreased
cocaine self-administration, while corticosterone replace-
ment restored it (148). Specific GR disruption in dopami-
noceptive but not dopamine neurones decreased cocaine
self-administration (149), whereas GR disruption in either
type attenuates cocaine-induced CPP, with no effect on
morphine-induced behaviour (150). Morphine-induced
CPP depends on hippocampal and nucleus accumbens
GR (151). In male mice, overexpression of forebrain GR
results in heightened sensitization to cocaine as well as
anxiety (152).
There is also evidence of the pivotal role of GR in
studies of GR polymorphisms in humans, which have
revealed association of particular alleles with the initiation
of alcohol abuse in female adolescents (153). These and
further experimental data that now link addictive
behaviour and symptoms with corticosteroids, particu-
larly in response to cocaine, are summarized in Table 1.
Sex differences in addiction
The possibility of sex differences in responses to drugs of
addiction of brain CRH, POMC, neurosteroids and the
HPA axis has not been addressed anywhere in the
literature reviewed here. Sometimes, the sex of experi-
mental animals used is not actually given, although this is
rare. The impression is that studies are often performed on
animals of the same sex – male rats are frequently used – to
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Review G P Vinson and C H Brennan Addiction and the adrenal
cortex
6–14 2 :R6
http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0028
 2013 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Glucocorticoids and addiction. All the direct experimental evidence for the essential role of glucocorticoids has been obtained
in experimental animals, as illustrated here. Evidence from the human species is indirect and circumstantial but appears to support the
general conclusion that glucocorticoids, regulated by an expanded HPA axis, underlie the important features of addiction.
Species Effects Reference
Ratsa Corticosterone Administration Up to 100 mg/ml in drinking
water
Induced corticosterone self
administration
139
Up to 50 mg/animal per day Induced corticosterone self
administration
140
Up to 0.8 mg/kg implant Induced corticosterone self
administration
194
Stress induced Novel environment Induced amphetamine self
administration
195
Immobilisation Impaired HPA feedback in cocaine
habituated animals
28, 29
Synthesis blocked By metyrapone 50 mg/kg Reduced psychomotor effects of
cocaine, and reduced reinstatement
196
By metyrapone 100 mg/kg Reduced psychomotor effects of
cocaine, and reduced reinstatement
143
By metyrapone synergistic
with benzodiazepine
agonist oxazepam; up to
45 mg/kg: 20 mg/kg i.p.c
Reduced psychomotor effects of
cocaine, and reduced reinstatement
197
By adrenalectomyd Cocaine reinstatement reduced,
restored by corticosterone
replacement
198
Reduced Fos response to dopamine
agonist, enhanced dopamine
response to cocaine
199
Decreased cocaine-induced locomotor
sensitisation
200
With corticosterone hemi-
succinate replacement; up
to 3 mg/kg implant
Restoration of cocaine-induced
sensitisation
200
Levels in blood Unrelated to high or low responder to
cocaine classification
201
Levels in brain Related to high or low responder to
cocaine classification
109, 202
Miceb GR Antagonist, mifepristone
30 mg/kg i.p. (or, less
effective, MR antagonist
spironolacetone
20 mg/kg i.p.)
Reduced cocaine induced
reinforcement
203
Selective GR
depletion
In brain Decreased sensitisation to cocaine self
administration
148
In brain Selective reduced glutamate receptor
subunit, and enkephalin response to
cocaine, no effect on neuropeptide or
dopamine receptor response
204
In dopaminoceptive
neurones
Decreased cocaine self administration 149
In dopaminoceptive or
dopamine neurones
Decreased cocaine induced CPP 150
Selective GR
overexpression
In forebrain Increased cocaine sensitisation 152
Adrenalectomy With corticosterone (20 mg
in pellets) and adrenaline
(5 mg/kg s.c.) replacemente
Synergistic actions on restoration of
cocaine induced locomotor
sensitisation
141
aSprague Dawley strain except where stated
bOriginal strain usually C57B/6
cWistar rats
dLong Evans rats
eDBA/2 Rj strain
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minimize variance. Yet sex differences in addiction are
clear and the extensive evidence has been reviewed in
human subjects and in experimental animals. Thus,
women are more susceptible to addiction and are at
greater risk of relapse than men (154, 155), and female rats
are more susceptible than male rats. Substantial evidence
links this to gonadal hormones (156).
There is nevertheless good reason to speculate that
adrenocortical hormones are involved here as well. Both
humans and rats have sex differences in adrenocortical
function, and although different in nature, both may
contribute to sex differences in addiction.
In humans, differences in circulating cortisol in males
and females are marginal at most, though there may be
differences in responsiveness to ACTH (96, 157, 158).
However, the major product of the gland is in fact DHEA,
which is secreted not only as the free steroid, but also, and
predominantly, as the sulphate, DHEAS. Plasma concen-
trations of DHEA and DHEAS in young adult men are
about 12 nM and 10 mM respectively, compared with about
8 nM and !7 mM in women, levels decrease with age
but the sex differences are maintained (96, 159, 160, 161).
The point is that DHEA has been shown to be
protective against drugs of addiction, as previously
noted. Evidence from cerebrospinal fluid suggests that
adrenal DHEA, and even DHEAS, may reach the brain in
significant amounts (162), although how this relates to
amounts synthesized within the brain cannot be assessed.
Although no sex differences in cerebrospinal fluid were
reported, it remains plausible that men receive more DHEA
protection to addictive drugs than women (154, 162).
In rats, the situation is different, and there is no
significant adrenal secretion of DHEA. However, there is a
profound difference in secretion and circulating concen-
trations of corticosterone (the main glucocorticoid in the
rat); adult female adrenals are nearly twice the size of males;
and output of corticosterone is proportionately greater
(163, 164, 165, 166). Although as noted earlier, DHEA is
synthesized in the rat brain, there is no sex difference, and
brain concentrations are similar in males and females (167).
Accordingly, in the rat, it is plausible that heightened
sensitivity to addictive drugs in females is associated with
the higher circulating levels of corticosterone.
The adrenal, addiction and the clock
If it is the adrenal gland itself that is critical for HPA-
modulated addictive processes, then other factors that are
instrumental in generating adrenocortical responses
may be expected to interact with addiction. Of the
physiological stimuli that stimulate the adrenal cortex,
stress is the most prominent and relevant. However, an
equally potent regulator of the adrenal cortex is the clock.
That stress, however defined, facilitates addiction
in both patients and animal models is well understood
(168, 169, 170, 171, 172). It is deeply interesting to note
that clock time too has its effect on addictive craving
and behaviours, although this literature generally has
little reference to the HPA, but has been focused on the
pineal and melatonin in the brain of male mice (173), or,
primarily, on clock genes. Periodicity in PER1 and cocaine
sensitivity are associated in male rats and mice of various
strains (174), drug reinstatement can be suppressed by
photoperiod in male rats (175), and clock gene variants
are associated with cocaine sensitization in Drosophila
(176) as with addiction in mice (sex not given) (177) and
in humans, according to some authors (178, 179, 180, 181)
but not all (182). In men, alcohol consumption over a
26-hour period affected neither melatonin nor the cortisol
secretory diurnal variation (183, 184).
Autonomy of the adrenal
One feature of adrenocortical function that is hardly
considered, in relation to addiction or anything else, is
that mechanisms exist whereby the secretion of gluco-
corticoid appears to be regulated in part by local stimuli.
CRH is notable among these. The relationship between the
functions of hypothalamic CRH and CRH formed locally
in the adrenal is currently obscure. That the adrenal gland
of various species may secrete CRH from the medulla in
response to splanchnic nerve stimulation has been shown,
as has the direct stimulatory effect of CRH on corticoster-
oid secretion (185, 186, 187, 188). How does adrenal CRH
vary with addiction? This is a topic for the future.
Conclusion
There is a clear pattern in the relationship of HPA activation
to the development of addictive behaviours in response to
quite different drugs. What is it they all have in common?
Is there a unifying pathway that in so many cases leads
to what may sometimes appear to be an addiction to the
adrenal cortex and the secretion of glucocorticoids?
One point is becoming clear: CRH and POMC at
different brain sites have clear functional links with the
classical HPA (Fig. 1), and together, they may play similar
roles in the adaptation that underlies addictive behaviour.
They may be considered in the context of addiction as
an expanded HPA, of which the terminal, and crucial,
component is the adrenal cortex itself.
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The evidence for the key importance of the adrenal
cortex and glucocorticoids in behaviour and symptoms in
drug withdrawal and reinstatement seems conclusive.
Therapeutic control of glucocorticoid secretion or inhi-
bition of glucocorticoid action at its receptor may be
important future developments (148, 189) in what other-
wise is a bleak therapeutic landscape (48, 189, 190, 191).
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